A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  2003-03-17

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1073/pnas.0630420100PMID 12642669PMCID PMC153550
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Structure and functional expression of a human interleukin-8 receptor. Science. 1991. 253: 1278-1280.

  2009cited by this paper
• Unique Monoclonal Antibody Recognizing the Third Extracellular Loop of CXCR4 Induces Lymphocyte Agglutination and Enhances Human Immunodeficiency Virus Type 1-Mediated Syncytium Formation and Productive Infection

  2001cited by this paper
• Pharmacokinetics and Safety of AMD-3100, a Novel Antagonist of the CXCR-4 Chemokine Receptor, in Human Volunteers

  2000cited by this paper
• Promising anti-HIV therapeutic strategy with a small molecule CXCR4 antagonist.

  1999cited by this paper
• Determinant in Human Immunodeficiency Virus Type 1 for Efficient Replication under Cytokine-Induced CD4+ T-Helper 1 (Th1)- and Th2-Type Conditions

  1999cited by this paper
• A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity.

  1999cited by this paper
• The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract

  1998cited by this paper
• Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease

  1998cited by this paper
• AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor

  1998cited by this paper
• Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group.

  1998cited by this paper
• New Monoclonal Antibodies against a Recombinant Second Envelope Protein of Hepatitis C Virus

  1998cited by this paper
• Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

  1998cited by this paper
• T-Cell-Line-Tropic Human Immunodeficiency Virus Type 1 That Is Made Resistant to Stromal Cell-Derived Factor 1α Contains Mutations in the Envelope gp120 but Does Not Show a Switch in Coreceptor Use

  1998cited by this paper
• Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development

  1998cited by this paper
• Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4

  1997cited by this paper
• A Small Molecule CXCR4 Inhibitor that Blocks T Cell Line–tropic HIV-1 Infection

  1997cited by this paper
• A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

  1997cited by this paper
• Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.

  1997cited by this paper
• HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5

  1996cited by this paper
• Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1

  1996cited by this paper
• The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1

  1996cited by this paper
• Identification of a major co-receptor for primary isolates of HIV-1

  1996cited by this paper
• CC CKR5: A RANTES, MIP-1α, MIP-1ॆ Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1

  1996cited by this paper
• The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1

  1996cited by this paper
• HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor

  1996cited by this paper
• Molecular Cloning and Functional Characterization of a Novel Human CC Chemokine Receptor (CCR5) for RANTES, MIP-1β, and MIP-1α*

  1996cited by this paper
• CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1.

  1996cited by this paper
• The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry

  1996cited by this paper
• Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells

  1995cited by this paper
• Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells.

  1995cited by this paper
• Cloning and Functional Expression of a Human Eosinophil CC Chemokine Receptor (*)

  1995cited by this paper
• Molecular Cloning and Functional Expression of a Novel CC Chemokine Receptor cDNA from a Human Basophilic Cell Line (*)

  1995cited by this paper
• Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission.

  1994cited by this paper
• The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression.

  1994cited by this paper
• Rapid loss of CD4+ T cells in human-PBL-SCID mice by noncytopathic HIV isolates.

  1993cited by this paper
• Genotypic and phenotypic characterization of HIV-1 patients with primary infection.

  1993cited by this paper
• Selective long-term elimination of natural killer cells in vivo by an anti-interleukin 2 receptor beta chain monoclonal antibody in mice

  1993cited by this paper
• Lignified materials as medicinal resources. VI. Anti-HIV activity of dehydrogenation polymer of p-coumaric acid, a synthetic lignin, in a quasi-in-vivo assay system as an intermediary step to clinical trials.

  1993cited by this paper
• A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12,Lys7]-polyphemusin II).

  1992cited by this paper
• Structure and functional expression of a human interleukin-8 receptor.

  1991cited by this paper
• Human immunodeficiency virus infection of human-PBL-SCID mice.

  1991cited by this paper
• The phorbol ester TPA strongly inhibits HIV-1-induced syncytia formation but enhances virus production: possible involvement of protein kinase C pathway.

  1990cited by this paper
• Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds.

  1988cited by this paper
• Transmission and genetic shift of human immunodeficiency virus (HIV) in vivo.

  1987cited by this paper
• Detection and isolation of an acquired immune deficiency syndrome (AIDS)-related virus (HTLV-III/LAV) from a Japanese boy with AIDS-related complex.

  1986cited by this paper
• Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone

  1986cited by this paper
• Infection of human T-lymphotropic virus type-I (HTLV-I)-bearing MT-4 cells with HTLV-III (AIDS virus): chronological studies of early events.

  1985cited by this paper

• Antibody-Drug Conjugates Using CD4 Mimics and a Neutralizing Antibody as HIV-1 Entry Inhibitors.

  2025cites this paper
• Targeting the chemokine receptor CXCR4 for cancer therapies

  2025cites this paper
• CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment

  2023cites this paper
• MSX-122: Is an effective small molecule CXCR4 antagonist in cancer therapy?

  2022cites this paper
• Targeting CXCR4 and CD47 Receptors: An Overview of New and Old Molecules for a Biological Personalized Anticancer Therapy

  2022cites this paper
• A fragment integrational approach to GPCR inhibition: Identification of a high affinity small molecule CXCR4 antagonist.

  2022cites this paper
• CXCR4-targeted metal complexes for molecular imaging

  2020cites this paper
• Nanotechnology: A Curative Approach to Combat HIV-AIDS

  2020cites this paper
• Efficiency of Homology Modeling assisted Molecular Docking in G-protein coupled receptors.

  2020cites this paper
• At the Bench: Pre‐clinical evidence for multiple functions of CXCR4 in cancer

  2020cites this paper
• Design, synthesis and biological evaluation of low molecular weight CXCR4 ligands.

  2019cites this paper
• The chemical diversity and structure-based evolution of non-peptide CXCR4 antagonists with diverse therapeutic potential.

  2018cites this paper
• Development of Stem-Cell-Mobilizing Agents Targeting CXCR4 Receptor for Peripheral Blood Stem Cell Transplantation and Beyond.

  2018cites this paper
• The role of CXCL12 in tumor microenvironment.

  2018cites this paper
• Conformational-Restricted Cyclic Peptides

  2018cites this paper
• Harnessing CXCR4 antagonists in stem cell mobilization, HIV infection, ischemic diseases, and oncology

  2018cites this paper
• SUBSTITUTED BENZODIAZEPINES AS INHIBITORS OF THE CHEMOKINE RECEPTOR CXCR4 CROSS-REFERENCE TO RELATED APPLICATIONS

  2017cites this paper
• “Fusion and binding inhibition” key target for HIV-1 treatment and pre-exposure prophylaxis: targets, drug delivery and nanotechnology approaches

  2017cites this paper
• CXCR4 Ligands: The Next Big Hit?

  2017cites this paper
• Structural Analysis of Chemokine Receptor–Ligand Interactions

  2017cites this paper
• Mutations in the CXCR4 gene cause a population shift in the feline lymphoma cell line 3201 surviving feline immunodeficiency virus infection

  2017cites this paper
• Synthesis & Evaluation Of Thiophene Derivatives As CXCR4 Antagonists

  2017cites this paper
• Discovery of non-peptide small molecular CXCR4 antagonists as anti-HIV agents: Recent advances and future opportunities.

  2016cites this paper
• Multi-objective active machine learning rapidly improves structure–activity models and reveals new protein–protein interaction inhibitors

  2016cites this paper
• Probing the molecular interactions between CXC chemokine receptor 4 (CXCR4) and the tripeptidomimetic antagonist KRH‐ 1636

  2016cites this paper
• Molecular Pathways: Targeting the CXCR4–CXCL12 Axis—Untapped Potential in the Tumor Microenvironment

  2015cites this paper
• Progress toward rationally designed small-molecule peptide and peptidomimetic CXCR4 antagonists.

  2015cites this paper
• Novel Prospective Treatment Options

  2015cites this paper
• AMD3100/CXCR4 Inhibitor

  2015cites this paper
• Stem cell mobilizers targeting chemokine receptor CXCR4: renoprotective application in acute kidney injury.

  2015cites this paper
• Probing the Molecular Interactions between CXC Chemokine Receptor 4 (CXCR4) and an Arginine-Based Tripeptidomimetic Antagonist (KRH-1636).

  2015cites this paper
• Progress in studies of structure, mechanism and antagonists interaction of GPCR co-receptors for HIV.

  2014cites this paper
• Papel de la quimiocina CXCL12/SDF-1 en la evolución del tropismo viral en la infección por el VIH-1

  2014cites this paper
• Toward Tripeptidomimetic CXCR4 Antagonists: Design, Synthesis, Biological Evaluation, and Binding Mode Studies

  2014cites this paper
• CXCR4-derived synthetic peptides inducing anti-HIV-1 antibodies.

  2013cites this paper
• Structure-based development of antagonists for chemokine receptor CXCR4.

  2013cites this paper
• Anti‐HIV‐1 Peptide Derivatives Based on the HIV‐1 Co‐receptor CXCR4

  2013cites this paper
• Small Molecule Inhibitors of CXCR4

  2013cites this paper
• Antiviral Drug Development – Success and Failure: A Personal Perspective with a Japanese Connection

  2013cites this paper
• Low‐Molecular‐Weight CXCR4 Ligands with Variable Spacers

  2013cites this paper
• Highly SpecIfic and Sensitive Pharmacophore Model for Identifying CXCR4 Antagonists. Comparison with Docking and Shape-Matching Virtual Screening Performance

  2013cites this paper
• A conformationally frozen peptoid boosts CXCR4 affinity and anti-HIV activity.

  2012cites this paper
• G protein-coupled receptors--recent advances.

  2012cites this paper
• Chemokine-dependent B cell–T cell interactions in chronic lymphocytic leukemia and multiple myeloma – targets for therapeutic intervention?

  2012cites this paper
• Peptide and peptidomimetic ligands for CXC chemokine receptor 4 (CXCR4).

  2012cites this paper
• Discovery of Novel Stem Cell Mobilizers That Target the CXCR4 Receptor

  2012cites this paper
• Impact of the CXCR4 structure on docking-based virtual screening of HIV entry inhibitors.

  2012cites this paper
• Single oral administration of the novel CXCR4 antagonist, KRH-3955, induces an efficient and long-lasting increase of white blood cell count in normal macaques, and prevents CD4 depletion in SHIV-infected macaques: a preliminary study

  2012cites this paper
• Erhöhte CXCR4‐Affinität und Anti‐HIV‐Aktivität eines Peptoids durch Konformationsfixierung

  2012cites this paper
• Novel compounds inhibiting HIV infection, breast cancer metastasis, and bacterial growth

  2012cites this paper
• Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4

  2012cites this paper
• [Clinical relevance of chemokine receptor CXCR4].

  2012cites this paper
• Pharmacophore-based small molecule CXCR4 ligands.

  2012cites this paper
• Application of affinity selection-mass spectrometry assays to purification and affinity-based screening of the chemokine receptor CXCR4.

  2012cites this paper
• Imaging-Based Assay for Identification and Characterization of Inhibitors of CXCR4-Tropic HIV-1 Envelope-Dependent Cell-Cell Fusion

  2011cites this paper
• PET Imaging of CXCR4 Receptors in Cancer by a New Optimized Ligand

  2011cites this paper
• Azamacrocyclic Metal Complexes as CXCR4 Antagonists

  2011cites this paper
• The successes and failures of HIV drug discovery

  2011cites this paper
• Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4).

  2011cites this paper
• The CXCL12/CXCR4 axis as a therapeutic target in cancer and HIV-1 infection.

  2011cites this paper
• Design, synthesis, and functionalization of dimeric peptides targeting chemokine receptor CXCR4.

  2011cites this paper
• Agonists for the Chemokine Receptor CXCR4

  2011cites this paper
• Applying in silico tools to the discovery of novel CXCR4 inhibitors

  2011cites this paper
• Computational analysis of the structural mechanism of inhibition of chemokine receptor CXCR4 by small molecule antagonists

  2011cites this paper
• HIV-1 (co)receptors: implications for vaccine and therapy design.

  2010cites this paper
• Differential CXCR4 expression and function in subpopulations of the feline lymphoma cell line 3201 susceptible to feline immunodeficiency virus

  2010cites this paper
• CXCL12-CXCR4 axis in angiogenesis, metastasis and stem cell mobilization.

  2010cites this paper
• An overview on different classes of viral entry and respiratory syncitial virus (RSV) fusion inhibitors.

  2010cites this paper
• HIV microbicides: state-of-the-art and new perspectives on the development of entry inhibitors.

  2010cites this paper
• Role of CXCR4 in HIV infection and its potential as a therapeutic target.

  2010cites this paper
• Novel Compounds Containing Multiple Guanide Groups That Bind the HIV Coreceptor CXCR4

  2010cites this paper
• Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers.

  2010cites this paper
• Synthesis of a novel tricyclic 1,2,3,4,4a,5,6,10b-octahydro-1,10-phenanthroline ring system and CXCR4 antagonists with potent activity against HIV-1.

  2010cites this paper
• The Novel CXCR 4 Antagonist KRH-3955 Is an Orally Bioavailable and Extremely Potent Inhibitor of Human Immunodeficiency Virus Type 1 Infection : Comparative Studies with AMD 3100

  2009influential citation
• Discovery of Novel HIV Entry Inhibitors for the CXCR4 Receptor by Prospective Virtual Screening

  2009cites this paper
• The Novel CXCR4 Antagonist KRH-3955 Is an Orally Bioavailable and Extremely Potent Inhibitor of Human Immunodeficiency Virus Type 1 Infection: Comparative Studies with AMD3100

  2009influential citation
• Chemokine receptor CXCR4 as a therapeutic target for neuroectodermal tumors.

  2009cites this paper
• HIV entry inhibitors and their potential in HIV therapy

  2009cites this paper
• CXCR4 chemokine receptor antagonists: perspectives in SCLC

  2009cites this paper
• Amine substituted N-(1H-benzimidazol-2ylmethyl)-5,6,7,8-tetrahydro-8-quinolinamines as CXCR4 antagonists with potent activity against HIV-1.

  2009cites this paper
• Investigations of binding mode for the cyclopentapeptide CXCR4 antagonist FC131 by induced fit docking

  2009cites this paper
• Entry Inhibitors of Human Immunodeficiency Virus

  2009cites this paper
• Etude des inhibiteurs d'entrée de CXCR4 : corécepteur d'entrée du virus de l'immunodéficience humaine

  2009cites this paper
• Design og syntese av cyklopentapeptidbaserte CXCR4 antagonister: Variasjon av essensiell aromatisk substituent

  2009cites this paper
• Targeting CXCR4 in HIV cell-entry inhibition.

  2009cites this paper
• Potential New Therapeutic Agents: Effects on HIV Replication and Viral Escape

  2009cites this paper
• Efficient inhibition of SDF‐1α‐mediated chemotaxis and HIV‐1 infection by novel CXCR4 antagonists

  2009cites this paper
• Structure-activity relationship study on artificial CXCR4 ligands possessing the cyclic pentapeptide scaffold: the exploration of amino acid residues of pentapeptides by substitutions of several aromatic amino acids.

  2009cites this paper
• Imidazopyridine-5,6,7,8-tetrahydro-8-quinolinamine derivatives with potent activity against HIV-1.

  2009cites this paper
• Chemokine receptor antagonists: part 2

  2009cites this paper
• Targeting the CXCR4/CXCL12 axis in systemic lupus erythematosus

  2009influential citation
• CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers

  2009cites this paper
• Edición por APOBEC, un nuevo mecanismo de resistencia a la infección por el VIH-1

  2008cites this paper
• Significant Virus Replication in Langerhans Cells following Application of HIV to Abraded Skin: Relevance to Occupational Transmission of HIV1

  2008cites this paper
• Exploratory Studies on Development of the Chemokine Receptor CXCR4 Antagonists Toward Downsizing

  2008cites this paper
• Small molecules anti-HIV therapeutics targeting CXCR4.

  2008cites this paper
• CXCR4 Chemokine Receptor

  2008cites this paper
• Design and synthesis of novel cyclopentapeptide antagonist for the chemokine receptor CXCR4

  2008cites this paper
• CXCR4, Inhibitors and Mechanisms of Action

  2008cites this paper
• Identification of novel non-peptide CXCR4 antagonists by ligand-based design approach.

  2008cites this paper